Ga-68 Somatostatin Receptor PET/CT in von Hippel-Lindau Disease

Jong-Ryool Oh,Harshad Kulkarni,Cecilia Carreras,Georg Schalch,Jung-Joon Min,Richard P. Baum
DOI: https://doi.org/10.1007/s13139-012-0133-0
2012-04-27
Nuclear Medicine and Molecular Imaging
Abstract:Von Hippel-Lindau (VHL) disease is a dominantly inherited familial cancer syndrome with a variety of benign and malignant tumors such as retinal and central nervous system hemangioblastomas, endolymphatic sac tumors, renal cysts and tumors, pancreatic cysts and tumors, pheochromocytomas, and epididymal cystadenomas. Cross-sectional modalities (computed tomography and magnetic resonance imaging) as well as ultrasound play a major role in the initial evaluation and follow-up of the various manifestations of VHL disease. Ga-68-labeled somatostatin receptor analogs already have a significant role in the diagnosis, staging, and therapy management of neuroendocrine neoplasms and neural crest tumors. Herein, we report a case presenting a variety of malignancies in VHL and showing the usefulness of Ga-68 somatostatin receptor PET/CT as a one-stop-shop imaging modality in the management of VHL disease.
What problem does this paper attempt to address?